Carbohydrate-binding agents: a potential future cornerstone for the chemotherapy of enveloped viruses?
Identifieur interne : 000A87 ( 2020/Analysis ); précédent : 000A86; suivant : 000A88Carbohydrate-binding agents: a potential future cornerstone for the chemotherapy of enveloped viruses?
Auteurs : Jan Balzarini [Belgique]Source :
- Antiviral chemistry & chemotherapy [ 0956-3202 ] ; 2007.
Descripteurs français
- KwdFr :
- MESH :
English descriptors
- KwdEn :
- MESH :
- chemical , pharmacology : Antiviral Agents.
- drug effects : HIV, Hepacivirus, SARS Virus.
- Animals, Carbohydrate Metabolism, Drug Resistance, Viral, Humans.
Abstract
Carbohydrate-binding agents (CBAs) inhibit HIV-1 and it is proposed that therapy with such agents may have important implications for the future of anti-HIV therapy. Examples of CBAs include the procaryotic cyanovirin-N (CV-N), plant lectins such as HHA, GNA, NPA, CA and UDA, the monoclonal antibody 2G12 directed against a glycan-containing epitope on HIV envelope gp120, and the mannose-specific non-peptidic antibiotic Pradimicin A, which inhibits the entry of HIV-1 into its target cells. CBAs prevent not only virus infection of susceptible cells, but also inhibit syncytia formation between persistently HIV-infected cells and uninfected lymphocytes. In addition, CBAs may also prevent DC-SIGN-mediated transmission of HIV to T-lymphocytes. Therefore, CBAs qualify as potential microbicide drugs. Long-term exposure of HIV to CBAs in cell culture results in the progressive deletion of N-glycans of HIV gpl20 in an attempt of the virus to escape drug pressure. In this respect, the CBAs are endowed with a high genetic barrier. Multiple mutations at N-glycosylation sites are required before pronounced phenotypic drug resistance development becomes evident. CBA treatment of HIV may consist of a novel chemotherapeutic concept with a dual mechanism of antiviral action: a direct antiviral activity by preventing HIV entry and transmission to its target cells, and an indirect antiviral activity by forcing HIV to delete glycans in its gpl20 envelope. The latter phenomenon will result in creating 'holes' in the protective glycan shield of the HIV envelope, whereby the immune system may become triggered to produce neutralizing antibodies against previously hidden immunogenic epitopes of gp120. If this concept can be proven in in vivo, low-molecular-weight non-peptidic CBAs such as Pradimycin A may become the cornerstone for the efficient treatment of infections of those viruses that require a glycosylated envelope (that is, HIV, but also hepatitis C virus) for entry into its target cells. In addition, influenza virus and coronavirus infections may also qualify to be treated by CBAs.
DOI: 10.1177/095632020701800101
PubMed: 17354647
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001E75
- to stream PubMed, to step Curation: 001E75
- to stream PubMed, to step Checkpoint: 001E64
- to stream Ncbi, to step Merge: 001896
- to stream Ncbi, to step Curation: 001896
- to stream Ncbi, to step Checkpoint: 001896
- to stream Main, to step Merge: 003911
- to stream Main, to step Curation: 003762
- to stream Main, to step Exploration: 003762
- to stream 2020, to step Extraction: 000A87
Links to Exploration step
pubmed:17354647Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Carbohydrate-binding agents: a potential future cornerstone for the chemotherapy of enveloped viruses?</title>
<author><name sortKey="Balzarini, Jan" sort="Balzarini, Jan" uniqKey="Balzarini J" first="Jan" last="Balzarini">Jan Balzarini</name>
<affiliation wicri:level="1"><nlm:affiliation>Rega Institute for Medical Research, K.U. Leuven, Leuven, Belgium. jan.balzarini@rega.kuleuven.be</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Rega Institute for Medical Research, K.U. Leuven, Leuven</wicri:regionArea>
<wicri:noRegion>Leuven</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2007">2007</date>
<idno type="RBID">pubmed:17354647</idno>
<idno type="pmid">17354647</idno>
<idno type="doi">10.1177/095632020701800101</idno>
<idno type="wicri:Area/PubMed/Corpus">001E75</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001E75</idno>
<idno type="wicri:Area/PubMed/Curation">001E75</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001E75</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001E64</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001E64</idno>
<idno type="wicri:Area/Ncbi/Merge">001896</idno>
<idno type="wicri:Area/Ncbi/Curation">001896</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001896</idno>
<idno type="wicri:doubleKey">0956-3202:2007:Balzarini J:carbohydrate:binding:agents</idno>
<idno type="wicri:Area/Main/Merge">003911</idno>
<idno type="wicri:Area/Main/Curation">003762</idno>
<idno type="wicri:Area/Main/Exploration">003762</idno>
<idno type="wicri:Area/2020/Extraction">000A87</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Carbohydrate-binding agents: a potential future cornerstone for the chemotherapy of enveloped viruses?</title>
<author><name sortKey="Balzarini, Jan" sort="Balzarini, Jan" uniqKey="Balzarini J" first="Jan" last="Balzarini">Jan Balzarini</name>
<affiliation wicri:level="1"><nlm:affiliation>Rega Institute for Medical Research, K.U. Leuven, Leuven, Belgium. jan.balzarini@rega.kuleuven.be</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Rega Institute for Medical Research, K.U. Leuven, Leuven</wicri:regionArea>
<wicri:noRegion>Leuven</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Antiviral chemistry & chemotherapy</title>
<idno type="ISSN">0956-3202</idno>
<imprint><date when="2007" type="published">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Carbohydrate Metabolism</term>
<term>Drug Resistance, Viral</term>
<term>HIV (drug effects)</term>
<term>Hepacivirus (drug effects)</term>
<term>Humans</term>
<term>SARS Virus (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Antiviraux (pharmacologie)</term>
<term>Hepacivirus ()</term>
<term>Humains</term>
<term>Métabolisme des glucides</term>
<term>Résistance virale aux médicaments</term>
<term>VIH (Virus de l'Immunodéficience Humaine) ()</term>
<term>Virus du SRAS ()</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>HIV</term>
<term>Hepacivirus</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Carbohydrate Metabolism</term>
<term>Drug Resistance, Viral</term>
<term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Hepacivirus</term>
<term>Humains</term>
<term>Métabolisme des glucides</term>
<term>Résistance virale aux médicaments</term>
<term>VIH (Virus de l'Immunodéficience Humaine)</term>
<term>Virus du SRAS</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Carbohydrate-binding agents (CBAs) inhibit HIV-1 and it is proposed that therapy with such agents may have important implications for the future of anti-HIV therapy. Examples of CBAs include the procaryotic cyanovirin-N (CV-N), plant lectins such as HHA, GNA, NPA, CA and UDA, the monoclonal antibody 2G12 directed against a glycan-containing epitope on HIV envelope gp120, and the mannose-specific non-peptidic antibiotic Pradimicin A, which inhibits the entry of HIV-1 into its target cells. CBAs prevent not only virus infection of susceptible cells, but also inhibit syncytia formation between persistently HIV-infected cells and uninfected lymphocytes. In addition, CBAs may also prevent DC-SIGN-mediated transmission of HIV to T-lymphocytes. Therefore, CBAs qualify as potential microbicide drugs. Long-term exposure of HIV to CBAs in cell culture results in the progressive deletion of N-glycans of HIV gpl20 in an attempt of the virus to escape drug pressure. In this respect, the CBAs are endowed with a high genetic barrier. Multiple mutations at N-glycosylation sites are required before pronounced phenotypic drug resistance development becomes evident. CBA treatment of HIV may consist of a novel chemotherapeutic concept with a dual mechanism of antiviral action: a direct antiviral activity by preventing HIV entry and transmission to its target cells, and an indirect antiviral activity by forcing HIV to delete glycans in its gpl20 envelope. The latter phenomenon will result in creating 'holes' in the protective glycan shield of the HIV envelope, whereby the immune system may become triggered to produce neutralizing antibodies against previously hidden immunogenic epitopes of gp120. If this concept can be proven in in vivo, low-molecular-weight non-peptidic CBAs such as Pradimycin A may become the cornerstone for the efficient treatment of infections of those viruses that require a glycosylated envelope (that is, HIV, but also hepatitis C virus) for entry into its target cells. In addition, influenza virus and coronavirus infections may also qualify to be treated by CBAs.</div>
</front>
</TEI>
<affiliations><list><country><li>Belgique</li>
</country>
</list>
<tree><country name="Belgique"><noRegion><name sortKey="Balzarini, Jan" sort="Balzarini, Jan" uniqKey="Balzarini J" first="Jan" last="Balzarini">Jan Balzarini</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/2020/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A87 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd -nk 000A87 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= 2020 |étape= Analysis |type= RBID |clé= pubmed:17354647 |texte= Carbohydrate-binding agents: a potential future cornerstone for the chemotherapy of enveloped viruses? }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/RBID.i -Sk "pubmed:17354647" \ | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
This area was generated with Dilib version V0.6.33. |